193 related articles for article (PubMed ID: 37674690)
1. Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review.
Ingold C; Navarro PA; de Oliveira R; Barbosa CP; Bedoschi G
Ther Adv Reprod Health; 2023; 17():26334941231196545. PubMed ID: 37674690
[TBL] [Abstract][Full Text] [Related]
2. Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy.
Massarotti C; Stigliani S; Gazzo I; Lambertini M; Anserini P
ESMO Open; 2023 Aug; 8(4):101597. PubMed ID: 37421801
[TBL] [Abstract][Full Text] [Related]
3. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.
Christ J; Herndon CN; Yu B
J Assist Reprod Genet; 2021 Mar; 38(3):751-756. PubMed ID: 33471229
[TBL] [Abstract][Full Text] [Related]
4. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
[TBL] [Abstract][Full Text] [Related]
5. Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome.
Marin L; Vitagliano A; Capobianco G; Dessole F; Ambrosini G; Andrisani A
J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101815. PubMed ID: 32562778
[TBL] [Abstract][Full Text] [Related]
6. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
8. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
9. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
10. Prednisone combined with letrozole reduced risk of ovarian hyperstimulation syndrome (OHSS) in women undergoing long-term gonadotropin-releasing hormone analog treatment.
Fang L; Ruan M; Yang S; Qu X; Chen H; Zhao J; Cheng J
Ann Palliat Med; 2021 Aug; 10(8):8837-8847. PubMed ID: 34488372
[TBL] [Abstract][Full Text] [Related]
11. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
[TBL] [Abstract][Full Text] [Related]
12. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.
Albuquerque LE; Tso LO; Saconato H; Albuquerque MC; Macedo CR
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD002808. PubMed ID: 23440788
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
Ups J Med Sci; 2020 May; 125(2):131-137. PubMed ID: 32366146
[TBL] [Abstract][Full Text] [Related]
14. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
Albuquerque LE; Saconato H; Maciel MC
Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
16. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
[TBL] [Abstract][Full Text] [Related]
17. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
Albuquerque LE; Saconato H; Maciel MC
Cochrane Database Syst Rev; 2005 Jan; (1):CD002808. PubMed ID: 15674898
[TBL] [Abstract][Full Text] [Related]
18. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
20. Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues.
Park SY; Jeong K; Cho EH; Chung HW
Clin Exp Reprod Med; 2021 Mar; 48(1):1-10. PubMed ID: 33131234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
